Abstract
Ornithine transcarbamylase deficiency (OTCD), the X-linked, most frequent urea cycle error, results from mutations in the OTC gene, encoding a 354-residue polypeptide. To date 341 OTCD clinical mutations, including 222 missense single nucleotide changes (mSNCs), have been compiled (Hum Mutat 2006;27:626). OTCD mutation detection might be simplified if the entire repertoire of OTCD-causing mutations were known. We estimate the size of this repertoire from 23 new OTCD patients exhibiting 22 different mutations, of which 9, including 4 mSNCs, are novel. The complete repertoire of OTCD-causing mutations is estimated as 560 mutations (95% confidence interval, 422–833 mutations), including 290 mSNCs (95% confidence interval, 230–394 mSNCs). Thus, OTCD diagnosis based on the screening for known mutations might attain ˜90% sensitivity in <5 years. Since disease-causing mSNCs represent <20% of the 2064 possible OTC mSNCs, simple approaches are essential for discrimination between causative and trivial mSNCs. Observation of the OTC structure appears a simple approach for such discrimination, comparing favourably in our sample with three formalized structure-based and/or sequence-based in silico assessment methods, and supporting the causation of complete deficiency by the mutations p.Pro305Arg and p.Ser96Phe, and of partial deficiency by p.Asp41Gly, p.Glu122Gly, p.Leu179Phe, p.Pro220Thr and p.Glu273del. Five non-mSNC novel mutations (p.Gly71X, a 7-nucleotide and a 10-nucleotide duplication and deletion in exon 5, G>A transitions at bases +1 and +5 of introns 4 and 9, respectively) are obviously pathogenic. The previously reported mSNCs p.Arg26Gln, p.Arg40His, p.Glu52Lys, pLys88Asn, p.Arg129His, p.Asn161Ser, p.Thr178Met, p.His202Tyr, p.Ala208Thr and p.His302Arg, found in our cohort, are also discussed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- CI:
-
confidence interval
- mSNC:
-
missense single nucleotide change
- nSNC:
-
nonsense single nucleotide change
- OTC:
-
ornithine transcarbamylase
- OTCD:
-
ornithine transcarbamylase deficiency
- PALO:
-
phosphonoacetyl-l-ornithine
- SNC:
-
single nucleotide change
- SSCP:
-
single-strand conformational polymorphism
References
Antonarakis SE, Krawczak M, Cooper DN (2001) The nature and mechanisms of human gene mutation. In: Scriver CR, Beaudet Al, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 343–377.
Bernstein HJ (2000) Recent changes to RasMol, recombining the variants. Trends Biochem Sci 25: 453–455.
Bhardwaj U, Zhang YH, McCabe ER (2003) Neonatal hemoglobinopathy screening: molecular genetic technologies. Mol Genet Metab 80: 129–137.
Brusilow SW, Horwich AL (2001) Urea cycle enzymes. In: Scriver CR, Beaudet~Al, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 1909–1963.
Climent C, Rubio V (2002) Identification of seven novel missense mutations, two splice-site mutations, two microdeletions and a polymorphic amino acid substitution in the gene for ornithine transcarbamylase (OTC) in patients with OTC deficiency. Hum Mutat 19: 185–186.
Doménech i Massons JM (1980) Bioestadística. Métodos estadísticos para investigadores. Barcelona: Herder, 61–91.
Galvin P, Clarke LA, Harvey S, Amaral MD (2004) Microarray analysis in cystic fibrosis. J Cys. Fibros 3(Suppl 2): 29–33.
Garcia-Perez MA, Sanjurjo P, Rubio V (1995) Demonstration of the spf-ash mutation in Spanish patients with ornithine transcarbamylase deficiency of moderate severity. Hum Genet 95: 183–186.
Genet S, Cranston T, Middleton-Price HR (2000) Mutation detection in 65 families with a possible diagnosis of ornithine carbamoyltransferase deficiency including 14 novel mutations. J Inherit Metab Dis 23: 669–676.
Green NS, Pass KA (2005) Neonatal screening by DNA microarray: spots and chips. Nat Rev Genet 6: 147–151.
Grompe M, Muzny DM, Caskey CT (1989) Scanning detection of mutations in human ornithine transcarbamoylase by chemical mismatch cleavage. Proc Natl Acad Sci USA 86: 5888–5892.
Hata A, Tsuzuki T, Shimada K, Takiguchi M, Mori M, Matsuda I (1998) Structure of the human ornithine transcarbamylase gene. J Biochem (Tokyo) 103: 302–308.
Jin L, Seaton BA, Head JF (1997) Crystal structure at 2.8 Å resolution of anabolic ornithine transcarbamylase from Escherichia coli. Nature Struct Biol 4: 622–625.
Jones TA, Zou J, Cowan S, Kjeldgaard M (1991) Improved methods for building protein models in electron density maps and the localization of errors in these models. Acta Crystallogr Sect A 47: 110–119.
Kim GH, Choi JH, Lee HH, Park S, Kim SS, Yoo HW (2006) Identification of novel mutations in the human ornithine transcarbamylase (OTC) gene of Korean patients with OTC deficiency and transient expression of the mutant proteins in vitro. Hum Mutat 27: 1159.
Kraulis PJ (1991) MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 24: 946–950.
Lindgren V, de Martinville B, Horwich AL, Rosenberg LE, Francke U (1984) Human ornithine transcarbamylase locus mapped to band Xp21.1 near the Duchenne muscular dystrophy locus. Science 226: 698–700.
Matsuda I, Matsuura T, Nishiyori A, et~al (1996) Phenotypic variability in male patients carrying the mutant ornithine transcarbamylase (OTC) allele, Arg40His, ranging from a child with an unfavourable prognosis to an asymptomatic older adult. J Med Genet 33: 645–648.
McCullough BA, Yudkoff M, Batshaw ML, Wilson JM, Raper SE, Tuchman M (2000) Genotype spectrum of ornithine transcarbamylase deficiency: correlation with the clinical and biochemical phenotype. Am J Med Genet 93: 313–319.
Merritt EA, Murphy MEP (1994) Raster3D version 2.0. A program for photorealistic molecular graphics. Acta Crystallogr Sect D 50: 869–873.
Morizono H, Tuchman M, Rajagopal BS, et~al (1997) Expression, purification and kinetic characterization of wild-type human ornithine transcarbamylase and a recurrent mutant that produces ‘late onset’ hyperammonaemia. Biochem J 322: 625–631.
Ng PC, Henikoff S (2003) SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 31: 3812–3814.
Nuzum CT, Snodgrass PJ (1976) Multiple assays of the five urea-cycle enzymes in human liver homogenates. In: Grisolia S, Báguena R, Mayor F, eds. The Urea Cycle. New York: Wiley, 325–349.
Oppliger Leibundgut EO, Liechti-Gallati S, Colombo JP, Wermuth B (1995) Ornithine transcarbamylase deficiency: new sites with increased probability of mutation. Hum Genet 95: 191–196.
Oppliger Leibundgut EO, Wermuth B, Colombo JP, Liechti-Gallati S (1996) Ornithine transcarbamylase deficiency: characterization of gene mutations and polymorphisms. Hum Mutat 8: 333–339.
Raijman L (1976) Enzyme and reactant concentrations and the regulation of urea synthesis. In: Grisolia S, Báguena R, Mayor F, eds. The Urea Cycle. New York: Wiley, 243–254.
Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous SNCs: server and survey. Nucleic Acids Res 30: 3894–3900.
Reish O, Plante RJ, Tuchman M (1993) Four new mutations in the ornithine transcarbamylase gene. Biochem Med Metab Biol 50: 169–175.
Segues B, Veber PS, Rabier D, et~al (1996) A 3-base pair in-frame deletion in exon 8 (delGlu272/273) of the ornithine transcarbamylase gene in late-onset hyperammonemic coma. Hum Mutat 8: 373–374.
Shapiro MB, Senapathy P (1987) RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acids Res 15: 7155–7174.
Shi D, Morizono H, Aoyagi M, Tuchman M, Allewell NM (1998) 1.85-Å resolution crystal structure of human ornithine transcarbamoylase complexed with N-phosphonacetyl-l-ornithine. J Biol Chem 273: 34247–34254.
Shi D, Morizono H, Aoyagi M, Tuchman M, Allewell NM (2000) Crystal structure of human ornithine transcarbamylase complexed with carbamoyl phosphate and l-norvaline at 1.9 Å resolution. Proteins 39: 271–277.
Shi D, Morizono H, Yu X, Tong L, Allewell NM, Tuchman M (2001) Human ornithine transcarbamylase: crystallographic insights into substrate recognition and conformational changes. Biochem J 354: 501–509.
Tejedor D, Castillo S, Mozas P, et~al (2005). Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem 51: 1137–1144.
Tuchman M, Plante RJ (1995) Mutations and polymorphisms in the human ornithine transcarbamylase gene: mutation update addendum. Hum Mutat 5: 293–295.
Tuchman M, Plante RJ, McCann MT, Qureshi AA (1994) Seven new mutations in the human ornithine transcarbamylase gene. Hum Mutat 4: 57–60.
Tuchman M, Morizono H, Rajagopal BS, Plante RJ, Alewell NM (1997) Identification of ‘private’ mutations in patients with ornithine transcarbamylase deficiency. J Inherit Metab Dis 20: 525–527.
Tuchman M, Jaleel N, Morizono H, Sheehy L, Lynch MG (2002) Mutations and polymorphisms in the human ornithine transcarbamylase (OTC) gene. Hum Mutat 19: 93–107.
Van Diggelen OP, Zaremba J, He W, et~al (1996) Asymptomatic and late-onset ornithine transcarbamylase (OTC) deficiency in males of a five-generation family, caused by an A208T mutation. Clin Genet 50: 310–316.
Wang Z, Moult J (2001) SNCs, protein structure, and disease. Hum Mutat 17: 263–270.
Yamaguchi S, Brailey LL, Morizono H, Bale AE, Tuchman M (2006) Mutations and polymorphisms in the human ornithine transcarbamylase (OTC) gene. Hum Mutat 27: 626–632.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicating editor: Alberto Burlina
Competing interests: None declared
References to electronic databases: OMIM #311250; EC 2.1.3.3; HUGO-approved gene symbol, OTC; GenBank reference sequence for human OTC: NP_000522 for the amino acid sequence, NM_000531 for the mRNA sequence, NC_000023 for the gene sequence; PDB entry (http://www.rcsb.org/pdb) 1OTH for the human OTC structure.
Rights and permissions
About this article
Cite this article
Arranz, J.A., Riudor, E., Marco-Marín, C. et al. Estimation of the total number of disease-causing mutations in ornithine transcarbamylase (OTC) deficiency. Value of the OTC structure in predicting a mutation pathogenic potential. J Inherit Metab Dis 30, 217–226 (2007). https://doi.org/10.1007/s10545-007-0429-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-007-0429-x